Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DARE NASDAQ:PMCB NASDAQ:SKYE NASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDare Bioscience$3.27+5.1%$1.78$1.27▼$9.19$47.61M1.09356,238 shs2.37 million shsPMCBNuvilex$0.73-3.6%$0.71$0.63▼$1.51$7.87M0.46201,287 shs58,278 shsSKYESkye Bioscience$0.88+0.8%$0.74$0.57▼$5.75$30.82M3.03492,687 shs107,793 shsSNTISenti Biosciences$0.95+1.2%$0.94$0.77▼$3.88$29.71M2.09195,776 shs59,471 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDare Bioscience0.00%+4.46%+34.48%+32.95%-21.48%PMCBNuvilex0.00%-0.97%+9.46%-3.78%-37.58%SKYESkye Bioscience0.00%-22.31%+17.98%-8.65%-63.37%SNTISenti Biosciences0.00%-3.77%+19.12%+4.08%-69.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDare Bioscience$3.27+5.1%$1.78$1.27▼$9.19$47.61M1.09356,238 shs2.37 million shsPMCBNuvilex$0.73-3.6%$0.71$0.63▼$1.51$7.87M0.46201,287 shs58,278 shsSKYESkye Bioscience$0.88+0.8%$0.74$0.57▼$5.75$30.82M3.03492,687 shs107,793 shsSNTISenti Biosciences$0.95+1.2%$0.94$0.77▼$3.88$29.71M2.09195,776 shs59,471 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDare Bioscience0.00%+4.46%+34.48%+32.95%-21.48%PMCBNuvilex0.00%-0.97%+9.46%-3.78%-37.58%SKYESkye Bioscience0.00%-22.31%+17.98%-8.65%-63.37%SNTISenti Biosciences0.00%-3.77%+19.12%+4.08%-69.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAREDare Bioscience 2.33Hold$10.00205.81% UpsidePMCBNuvilex 1.00SellN/AN/ASKYESkye Bioscience 2.63Moderate Buy$9.801,017.19% UpsideSNTISenti Biosciences 2.80Moderate Buy$8.50790.99% UpsideCurrent Analyst Ratings BreakdownLatest PMCB, SKYE, SNTI, and DARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026PMCBNuvilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/21/2026SNTISenti Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026DAREDare Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/30/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAREDare Bioscience$1.03M46.22N/AN/A$0.20 per share16.35PMCBNuvilexN/AN/AN/AN/A$7.56 per shareN/ASKYESkye BioscienceN/AN/AN/AN/A$0.62 per shareN/ASNTISenti Biosciences$20K1,485.38N/AN/A$0.21 per share4.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAREDare Bioscience-$13.40M-$1.25N/AN/AN/AN/AN/A-56.52%5/12/2026 (Estimated)PMCBNuvilex$30.66M-$1.12N/AN/AN/AN/A2.13%1.69%7/1/2026 (Estimated)SKYESkye Bioscience-$55.92M-$1.40N/AN/AN/AN/A-143.59%-119.89%N/ASNTISenti Biosciences-$61.44M-$3.19N/AN/AN/AN/A-301.48%-90.03%5/5/2026 (Estimated)Latest PMCB, SKYE, SNTI, and DARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026DAREDare Bioscience-$0.33N/AN/AN/A$0.03 millionN/A5/5/2026Q1 2026SNTISenti Biosciences-$0.36N/AN/AN/A$0.02 millionN/A3/27/2026Q4 2025SNTISenti Biosciences-$0.43-$0.53-$0.10-$0.53$1.00 million$0.02 million3/26/2026Q4 2025DAREDare Bioscience-$0.44-$0.02+$0.42-$0.02$0.75 million$1.02 million3/10/2026Q4 2025SKYESkye Bioscience-$0.29-$0.36-$0.07-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDAREDare BioscienceN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAREDare BioscienceN/A1.141.14PMCBNuvilexN/A12.3312.33SKYESkye BioscienceN/A3.303.30SNTISenti BiosciencesN/A1.671.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAREDare Bioscience6.70%PMCBNuvilex34.24%SKYESkye Bioscience21.09%SNTISenti Biosciences25.70%Insider OwnershipCompanyInsider OwnershipDAREDare Bioscience4.80%PMCBNuvilex10.98%SKYESkye Bioscience3.00%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAREDare Bioscience3014.56 million13.86 millionNot OptionablePMCBNuvilex410.74 million9.56 millionOptionableSKYESkye Bioscience1135.13 million34.07 millionOptionableSNTISenti Biosciences431.14 million30.17 millionNot OptionablePMCB, SKYE, SNTI, and DARE HeadlinesRecent News About These CompaniesSenti Biosciences (SNTI) Expected to Announce Earnings on TuesdayMay 3 at 5:12 AM | americanbankingnews.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | markets.businessinsider.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | globenewswire.comSenti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell TherapiesApril 1, 2026 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateMarch 27, 2026 | globenewswire.comSenti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer ConferenceMarch 23, 2026 | globenewswire.comSenti Biosciences Amends Lease, Restructures GeneFab SubleaseMarch 19, 2026 | tipranks.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | tmcnet.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comSenti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care ConferenceFebruary 24, 2026 | quiverquant.comQSenti Biosciences to Present at TD Cowen 46th Annual Health Care ConferenceFebruary 24, 2026 | globenewswire.comSenti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy DevelopmentFebruary 20, 2026 | globenewswire.comSenti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)February 11, 2026 | globenewswire.comSenti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026February 3, 2026 | globenewswire.comSenti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting ...January 21, 2026 | uk.finance.yahoo.comSenti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and ...January 14, 2026 | tmcnet.comSenti Biosciences, Inc. Highlights FDA RMAT Designation for SENTI-202 in Virtual Investor CEO Connect SegmentJanuary 14, 2026 | quiverquant.comQSenti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT DesignationJanuary 14, 2026 | globenewswire.comSenti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare ConferenceJanuary 9, 2026 | globenewswire.comSenti Biosciences Announces New Employment Inducement GrantsDecember 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCB, SKYE, SNTI, and DARE Company DescriptionsDare Bioscience NASDAQ:DARE$3.27 +0.16 (+5.14%) Closing price 04:00 PM EasternExtended Trading$3.34 +0.08 (+2.29%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Nuvilex NASDAQ:PMCB$0.73 -0.03 (-3.55%) Closing price 03:59 PM EasternExtended Trading$0.73 0.00 (-0.14%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Skye Bioscience NASDAQ:SKYE$0.88 +0.01 (+0.83%) Closing price 04:00 PM EasternExtended Trading$0.90 +0.02 (+2.49%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Senti Biosciences NASDAQ:SNTI$0.95 +0.01 (+1.21%) Closing price 04:00 PM EasternExtended Trading$0.94 -0.01 (-1.26%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
